
DelNova, a biopharmaceutical company targeting unmet medical needs, by developing clinically validated molecules linked to advances in drug delivery, announced today that the company is making substantive progress in developing the first ever product to reverse complications arising from administration of botulinum toxin neuromodulators, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®. According to the syndicated… Read more »